A key challenge remains finding a delivery system that enables enough of the mRNA to reach target tissues safely without causing adverse effects. Lipid nanoparticles have been studied since the ...

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in ...

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

Reference: Patel MN, Tiwari S, Wang Y, et al. Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids. Nat Biotechnol. 2025. doi: ...

Marama Labs' CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The global lipid nanoparticles market, valued at US$ 820.51 million in 2023, is projected to experience significant growth, with an expected market valuation of US$ 2,387.98 million by 2032. This ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.